A Phase 3 interventional study of Sarilumab SAR153191 and Placebo in Corona Virus Infection, sponsored by Sanofi. Completed at 47 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-24.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 89 studies in Coronavirus Infections with a site in France — 4 open to participants now, 6 under way, 2 of them phase 3. Coronavirus Infections · France.
Among the 89 studies in Coronavirus Infections with a site in France, this one is the 14th largest by enrollment of the 45 interventional ones that give a count, is one of 78 that started in 2020, is one of 12 in phase 3, and was the 13th registered.
1,112 studies on the registry are indexed under Coronavirus Infections; 52 are open to participants now.
Browse Coronavirus Infections studies →4 of the 89 studies in Coronavirus Infections with a site in France are open now. Recruiting first, the newest first:
Pfizer · Sites in France, United States, Argentina and 15 more countries
Ages 18+
Centre Hospitalier Universitaire de Nīmes · Sites in France
Ages 18+ · Healthy volunteers
AstraZeneca · Sites in France, United States, Argentina and 36 more countries
Ages 18+
Centre Hospitalier Universitaire de Nice · Sites in France
Ages 18+ · Healthy volunteers
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 40 Coronavirus Infections studies recruiting now, 24 (60%) set no upper age limit and 9 (23%) stop at 75 or younger; 13 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
89 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 10 · Phase 3 16
First in 2020; this study’s year is marked. 78 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 420 is above the median of 120 across 655 interventional studies indexed under Coronavirus Infections.
Median enrollment 228 across the 45 interventional studies, 407 across the 44 observational. Of the 70 that completed or were terminated, 9 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 89 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Sanofi has 3 studies filed under Coronavirus Infections — fewer than ten, so there is no comparison to draw.
2 of the studies in Coronavirus Infections with a site in France that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add all 2 to your calendar (.ics) → With an account.
Among the 89 studies in Coronavirus Infections with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To evaluate the clinical efficacy of sarilumab relative to the control arm in adult participants hospitalized with severe or critical Coronavirus Disease 2019 (COVID-19).
Secondary Objectives:
The secondary safety objectives of the study were to evaluate the safety of sarilumab through hospitalization (up to Day 29 if participant was still hospitalized) compared to the control arm as assessed by incidence of:
An individual participant would complete the study approximately 60 days from screening to follow-up on day 60 ±7 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must be >=18 years of age. Participants must be hospitalized for less than or equal to 7 days with evidence of pneumonia and have one of the following disease categories: severe disease or critical disease.
Laboratory-confirmed severe acute respiratory syndrome coronavirus 2 infection.
Exclusion criteria:
Unlikely to survive after 48 hours from screening or unlikely to remain at the site beyond 48 hours. Participants with multi organ dysfunction or requiring extracorporeal life support or renal replacement therapy were excluded.
Presence of neutropenia less than 2000/cubic millimeter (mmˆ3), or ALT greater than 5X , less than 50,000/mmˆ3.
Prior therapies. Use of systemic chronic for non-COVID-19 related condition. Known or suspected history of tuberculosis. Suspected or known active systemic bacterial or fungal infections.
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sarilumab 200 milligrams (mg), single dose of intravenous (IV) injection on Day 1. Participants could receive a second dose of sarilumab 200 mg 24 to 48 hours after the first dose if first and any one of last three criteria was met as compared to Day 1 (as per following protocol amendment 2 \[dated 08-Apr-2020\]): * Benefit risk assessment by the investigator favored the administration of another dose of study drug without compromising safety and * Increase/recurrence of fever or * Increase/no change in fraction of inspired oxygen (FiO2) requirement or * Required vasopressors, extracorporeal membrane oxygenation (ECMO) or development of multi-organ dysfunction.
Drug: Sarilumab SAR153191
Sarilumab 400 mg, single dose of IV injection on Day 1. Participants could receive a second dose of sarilumab 400 mg 24 to 48 hours after the first dose if first and any one of last three criteria was met as compared to Day 1 (as per following protocol amendment 2 \[dated 08-Apr-2020\]): * Benefit risk assessment by the investigator favored the administration of another dose of study drug without compromising safety and * Increase/recurrence of fever or * Increase/no change in FiO2 requirement or * Required vasopressors, ECMO or development of multi-organ dysfunction.
Drug: Sarilumab SAR153191
Placebo (for sarilumab), single dose of IV injection on Day 1. Participants could receive a second dose of placebo (for sarilumab) 24 to 48 hours after the first dose if first and any one of last three criteria was met as compared to Day 1 (as per following protocol amendment 2 \[dated 08-Apr-2020\]): * Benefit risk assessment by the investigator favored the administration of another dose of study drug without compromising safety and * Increase/recurrence of fever or * Increase/no change in FiO2 requirement or * Required vasopressors, ECMO or development of multi-organ dysfunction.
Drug: Placebo
Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
Also known as: REGN88, Kevzara®
Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
Time to Improvement in Clinical Status of Participants (Using 7-point Ordinal Scale Score) by at Least 2 Points
Time to improvement of greater than or equal (\>=) 2 points in clinical status assessment was defined as time (in days) from first dose of study drug to the time of first occurrence of improvement of \>=2 points in clinical status of participants assessed using 7-point ordinal scale (calculated as: Date of first occurrence/episode of the event - date of first dose + 1). Seven-point ordinal scale for clinical assessment ranges from 1= death; 2= hospitalized, on invasive mechanical ventilation/ECMO; 3= hospitalized, on non-invasive ventilation/high flow oxygen devices; 4= hospitalized, requiring supplemental oxygen; 5= hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related/otherwise); 6= hospitalized, not requiring supplemental oxygen - no longer required ongoing medical care; 7= not hospitalized, higher score = less severity. Kaplan-Meier method was used for analysis.
Time frame: Baseline to Day 29
Percentage of Participants Who Were Alive at Day 29
Percentage of participants who were alive at Day 29 were reported in this outcome measure.
Time frame: Day 29
Percentage of Participants With Improvement in Clinical Status (According to 7-point Ordinal Scale Score) by at Least 1 Point From Baseline at Days 4, 7, 15, 21, and 29
Clinical status of participants was assessed using 7-point ordinal scale ranges from: 1= death; 2= hospitalized, on invasive mechanical ventilation/ECMO; 3= hospitalized, on non-invasive ventilation/high flow oxygen devices; 4= hospitalized, requiring supplemental oxygen; 5= hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related/otherwise); 6= hospitalized, not requiring supplemental oxygen - no longer required ongoing medical care; 7= not hospitalized, higher score=less severity. Percentage of participants With \>=1 point improvement in clinical status from Baseline at Days 4, 7, 15, 21, and 29 (assessed using the 7-point ordinal scale) were reported.
Time frame: Baseline, Days 4, 7, 15, 21, and 29
Change From Baseline at Days 4, 7, 15, 21, 29 in 7-point Ordinal Scale Score
Clinical status of participants was assessed using 7-point ordinal scale ranges from: 1= death; 2= hospitalized, on invasive mechanical ventilation/ECMO; 3= hospitalized, on non-invasive ventilation/high flow oxygen devices; 4= hospitalized, requiring supplemental oxygen; 5= hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related/otherwise); 6= hospitalized, not requiring supplemental oxygen - no longer required ongoing medical care; 7= not hospitalized, higher score=less severity.
Time frame: Baseline, Days 4, 7, 15, 21, and 29
Time to Resolution of Fever
Resolution of fever was defined as body temperature less than or equal to (\<=) 36.6 degree Celsius (°C) (axilla), or \<=37.2°C (oral), or \<=37.8°C (rectal or tympanic) for at least 48 hours without antipyretics/until discharge, whichever was sooner. Time to resolution of fever (in days) was calculated as: date of first occurrence/episode of the event (resolution of fever) - date of first dose + 1. Kaplan-Meier method was used for estimation.
Time frame: Baseline to Day 29
Time to Resolution of Fever and Improvement in Oxygenation
Time to resolution of fever was defined as body temperature \<=36.6°C (axilla), or \<=37.2 °C (oral), or \<=37.8°C (rectal or tympanic) for at least 48 hours without antipyretics or until discharge, whichever was sooner. Improvement in oxygenation was defined as oxygen saturation (SpO2)/FiO2 of 50 or greater compared to the nadir SpO2/FiO2 for at least 48 hours, or until discharge, whichever was sooner. Nadir SpO2/FiO2 was the nadir (lowest value) at any point in the study. Time to resolution of fever and improvement in oxygenation (in days) was calculated as: date of first occurrence/episode of the event (resolution of fever and improvement in oxygenation) - date of first dose + 1. Kaplan-Meier method was used for estimation.
Time frame: Baseline to Day 29
Number of Days With Fever
Fever was defined as body temperature greater than (\>) 37.4°C (axilla), or \>38.0 °C (oral), or \>38.4°C (rectal or tympanic) based on maximum value observed during a 24-hour period. Number of days with fever were reported. Least square (LS) mean and standard error (SE) were estimated using the analysis of covariance (ANCOVA) model with treatment group and randomization strata as fixed effects.
Time frame: Baseline to Day 29
Percentage of Participants in Each National Early Warning Score 2 (NEWS2) Clinical Risk Category at Baseline and at Days 4, 7, 15, 21, and 29
NEWS2: used to standardize assessment of acute-illness severity, track clinical condition of participants and to alert clinical teams to participant deterioration. NEWS2 score was based on 7 clinical parameters: respiration rate, oxygen saturation, supplemental oxygen, systolic blood pressure, pulse rate, level of consciousness, and temperature. A score of 0, 1, 2, and 3 was allocated to each parameter except supplemental oxygen (a score of 0 or 1 was allocated) and level of consciousness (a score of 0 or 3 was allocated), where 0 = normal health condition to 3 = worst health condition; higher score indicated more severity. All scores were summed to get an aggregate score. Aggregate NEWS2 score ranged from 0 to 19, with higher scores meaning more severity/higher risk. Percentage of participants in following clinical risk categories were reported: low risk (score 0 to 4); low to medium risk (score of 3 in any individual parameter); medium risk (score 5 to 6); high risk (score 7 to 19).
Time frame: Baseline, Days 4, 7, 15, 21, and 29
Time to National Early Warning Score of Less Than (<) 2 and Maintained for 24 Hours
Time to NEWS2 \<2 and maintained for 24 hours: time (in days) from 1st dose of study drug until 1st occurrence of NEWS score of \<2 (maintained for 24 hours); calculated as: date of 1st occurrence/episode of event (NEWS score of \<2) - date of 1st dose + 1. NEWS2 score was based on 7 clinical parameters: respiration rate, oxygen saturation, supplemental oxygen, systolic blood pressure, pulse rate, level of consciousness, and temperature. A score of 0, 1, 2, and 3 was allocated to each parameter except supplemental oxygen (score of 0 or 1 was allocated) and level of consciousness (score of 0 or 3 was allocated), where 0=normal health condition to 3=worst health condition; higher score=more severity. All scores were summed to get an aggregate score which ranged from 0 to 19, with higher scores=more severity/higher risk. Kaplan-Meier method was used for analysis.
Time frame: Baseline to Day 29
Change From Baseline at Days 4, 7, 15, 21, and 29 in National Early Warning Score 2
The NEWS2 was used to standardize the assessment of acute-illness severity, track the clinical condition of participants, and to alert clinical teams to participant deterioration. NEWS2 score is based on 7 clinical parameters: respiration rate, oxygen saturation, supplemental oxygen, systolic blood pressure, pulse rate, level of consciousness, and temperature. A score of 0, 1, 2, and 3 was allocated to each parameter except supplemental oxygen (a score of 0 or 1 was allocated) and level of consciousness (a score of 0 or 3 was allocated), where 0 = normal health condition to 3 = worst health condition; higher score indicated more severity. All scores were summed to get an aggregate score. Aggregate NEWS2 score ranged from 0 to 19, with higher scores meaning more severity/higher risk. LS means and SE were estimated using ANCOVA model with treatment group and randomization strata as fixed effects, and baseline NEWS2 score as a covariate.
Time frame: Baseline, Days 4, 7, 15, 21, and 29
Time-to-improvement in Oxygenation
Time-to-improvement in oxygenation was defined as increase in SpO2/FiO2 of 50 or greater compared to the nadir SpO2/FiO2 for at least 48 hours or until discharge, whichever was sooner. Nadir SpO2/FiO2 was the nadir (lowest value) at any point in the study. Time to improvement in oxygenation was calculated as: date of first occurrence/episode of the event (oxygenation) - date of first dose + 1. Kaplan-Meier method was used for estimation.
Time frame: Baseline to Day 29
Percentage of Participants Alive Off Supplemental Oxygen at Day 29
Supplemental oxygen was defined as oxygen administration by nasal cannula, simple face mask, or other similar oxygen delivery device.
Time frame: Day 29
Percentage of Days With Hypoxemia
Hypoxemia (low level of oxygen in the blood) was defined as SpO2 \<93% on room air, or required supplemental oxygen, or mechanical ventilatory support. Days meeting the criteria for hypoxemia since the first study dose were counted and the percentage of days with hypoxemia were calculated as:100\*number of days with the hypoxemia divided by number of days of follow up (defined as the earlier date of death or discharge or last visit up to Day 29). LS mean and SE were estimated using the ANCOVA model with treatment group and randomization strata as fixed effects.
Time frame: Baseline to Day 29
Percentage of Days With Supplemental Oxygen Use
Supplemental oxygen (oxygen therapy) was defined as oxygen administration using oxygen delivery device (e.g. nasal cannula, simple face mask, non-rebreather mask, high flow nasal cannula, non-invasive ventilation, invasive mechanical ventilation, extracorporeal life support, etc.). Days meeting the criteria for supplemental oxygen use since the first study dose were counted and the percentage of days with supplemental oxygen use were calculated as:100\*number of days with the supplemental oxygen use divided by number of days of follow up (defined as the earlier date of death or discharge or last visit up to Day 29) . LS mean and SE were estimated using the ANCOVA model with treatment group and randomization strata as fixed effects.
Time frame: Baseline to Day 29
Percentage of Days With Resting Respiratory Rate > 24 Breaths Per Minute
Resting respiratory rate was measured in terms of number of breaths per minute (bpm) while a person is at rest. Only the days with respiratory rate \>24 breath per minute since the first dose were counted and percentage of days with respiratory rate \> 24 bpm were calculated as:100\*number of days with respiratory rate \>24 bpm divided by number of days of follow up (defined as the earlier date of death or discharge or last visit up to Day 29). LS mean and SE were estimated using the ANCOVA model with treatment group and randomization strata as fixed effects.
Time frame: Baseline to Day 29
Time to Oxygen Saturation >= 94% on Room Air
Time to oxygen saturation \>=94% on room air was defined as the time (in days) from first dose of study drug until the time of first occurrence of oxygen saturation \>=94% and it was calculated as: Date of first occurrence/episode of the event (oxygen saturation \>=94%) - date of first dose + 1.Kaplan-Meier method was used for estimation.
Time frame: Baseline to Day 29
Mean Number of Ventilator Free Days
Mean number of ventilator free days in participants were reported.
Time frame: Baseline to Day 29
Percentage of Participants With Initiation of Mechanical Ventilation, Non-invasive Ventilation, or Use of High Flow Nasal Cannula
Percentage of participants With initiation of mechanical ventilation or non-invasive ventilation, or use of high flow nasal cannula were reported in this outcome measure.
Time frame: Baseline to Day 29
Percentage of Participants Who Required Rescue Medication
Rescue medications were defined as the immunosuppressive (methylprednisolone, dexamethasone and prednisone) therapies. During the course of the study, participant who required rescue therapy was based on the judgement of the study physician.
Time frame: Baseline to Day 28
Percentage of Participants Who Needed Intensive Care Unit (ICU) Care During Study
Percentage of participants who needed ICU care until Day 29 were reported for those not in an ICU at baseline.
Time frame: Baseline to Day 29
Number of Days of Hospitalization Among Survivors (Alive Participants)
Number of days of hospitalization among alive participants were counted at Day 60 since the first dose. LS mean and SE were estimated using the ANCOVA model with treatment group and randomization strata as fixed effects.
Time frame: At Day 60
Number of Participants With Treatment-emergent Serious Adverse Events (SAEs)
An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had to have a causal relationship with the treatment. Treatment-emergent AEs (TEAEs) were the AEs that developed or worsened or became serious during the TEAE period (from the time of first dose of study drug to the last dose of study drug + 60 days). SAEs were any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event.
Time frame: Baseline up to 60 days
Number of Participants With Major or Opportunistic Bacterial or Fungal Infections
Major or opportunistic bacterial or fungal infections was considered as an adverse event of special interest (AESI: defined as an AE \[serious or non-serious\] of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor was required).
Time frame: Baseline up to 60 days
Number of Participants With Grade 4 Neutropenia and Grade 4 Neutropenia With Concurrent Invasive Infection
Grade 4 neutropenia was defined as participants with absolute neutrophil count (ANC) \<500 per cubic millimeter (mm\^3). Grade 4 neutropenia with concurrent invasive infection was defined as infections and infestations (in participants with Grade 4 neutropenia) within 1 week of ANC \<500/mm\^3 and was considered as an AESI (defined as an AE \[serious or non-serious\] of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor was required).
Time frame: Baseline up to 60 days
Number of Participants With Grade >=2 Infusion Reactions, Grade >=2 Hypersensitivity Reactions and Gastrointestinal Perforation
Grade \>=2 (moderate) infusion related reactions (defined as any TEAE signs or symptoms experienced by participants who received study medication within 24 hours of the start of infusion) and Grade \>=2 (moderate) hypersensitivity reactions (anaphylactic reaction, hypersensitivity or angioedema and moderate reactions) were considered as AESI which was defined as an AE (serious or non-serious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor was required. Gastrointestinal Perforation was defined as formation of a hole through the stomach, large bowel or small intestine.
Time frame: Baseline up to 60 days
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities (PCSA): Hematological Parameter - Hemoglobin, Leukocytes and Platelets
Criteria for PCSA: * Hemoglobin: less than or equal to (\<=) 115 grams per liter (g/L) (male) and \<=95 g/L (female); greater than or equal to (\>=) 185 g/L (male) and \>=165 g/L (female); and decrease from baseline \>=20 g/L. * Leukocytes: \<3.0\*10\^9/Liters (L) (Non-Black) or \<2.0\*10\^9/L (black); \>=16.0\*10\^9/L. * Platelets: \< 100\*10\^9/L; \>=700\*10\^9/L.
Time frame: Baseline up to 60 days
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Renal Function Parameters
Criteria for PCSA: Creatinine: \>=150 micromoles per liter (mcmol/L); \>=30% change from baseline; \>= 100% change from baseline.
Time frame: Baseline up to 60 days
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Liver Function Parameters
* Alanine Aminotransferase (ALT): \>3 upper limit of normal (ULN); \>5 ULN; \>10 ULN and \>20 ULN. * Bilirubin: \>1.5 ULN; \>2 ULN.
Time frame: Baseline up to 60 days
Study was conducted at 46 active centers in 11 countries. A total of 431 participants were screened between 28 March 2020 and 02 July 2020, of which 10 participants were screen failures and 1 participant was randomized twice and thus excluded. Therefore, a total of 420 participants were randomized in the study treatment by the interactive response technology (IRT) (2:2:1 ratio) to receive sarilumab 200 milligrams (mg)/400 mg and placebo. Screen failures were mainly due to exclusion criteria met.
| Milestone | Sarilumab 200 mg | Sarilumab 400 mg | Placebo |
|---|---|---|---|
| Started | 161 | 173 | 86 |
| Treated | 159 | 173 | 84 |
| Participants who received second dose | 13 | 11 | 5 |
| Completed | 141 | 153 | 75 |
| Not completed | 20 | 20 | 11 |
| Withdrew: Adverse event | 17 | 18 | 9 |
| Withdrew: Other | 1 | 2 | 0 |
| Withdrew: Randomized and not treated | 2 | 0 | 2 |
Time to improvement of greater than or equal (\>=) 2 points in clinical status assessment was defined as time (in days) from first dose of study drug to the time of first occurrence of improvement of \>=2 points in clinical status of participants assessed using 7-point ordinal scale (calculated as: Date of first occurrence/episode of the event - date of first dose + 1). Seven-point ordinal scale for clinical assessment ranges from 1= death; 2= hospitalized, on invasive mechanical ventilation/ECMO; 3= hospitalized, on non-invasive ventilation/high flow oxygen devices; 4= hospitalized, requiring supplemental oxygen; 5= hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related/otherwise); 6= hospitalized, not requiring supplemental oxygen - no longer required ongoing medical care; 7= not hospitalized, higher score = less severity. Kaplan-Meier method was used for analysis.
| days | Sarilumab 200 mg | Sarilumab 400 mg | Placebo |
|---|---|---|---|
| Time to Improvement in Clinical Status of Participants (Using 7-point Ordinal Scale Score) by at Least 2 Points | 10.0 (9.00 to 12.00) | 10.0 (9.00 to 13.00) | 12.0 (9.00 to 15.00) |
Percentage of participants who were alive at Day 29 were reported in this outcome measure.
| percentage of participants | Sarilumab 200 mg | Sarilumab 400 mg | Placebo |
|---|---|---|---|
| Percentage of Participants Who Were Alive at Day 29 | 89.9 | 91.9 | 91.7 |
Clinical status of participants was assessed using 7-point ordinal scale ranges from: 1= death; 2= hospitalized, on invasive mechanical ventilation/ECMO; 3= hospitalized, on non-invasive ventilation/high flow oxygen devices; 4= hospitalized, requiring supplemental oxygen; 5= hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related/otherwise); 6= hospitalized, not requiring supplemental oxygen - no longer required ongoing medical care; 7= not hospitalized, higher score=less severity. Percentage of participants With \>=1 point improvement in clinical status from Baseline at Days 4, 7, 15, 21, and 29 (assessed using the 7-point ordinal scale) were reported.
| percentage of participants | Sarilumab 200 mg | Sarilumab 400 mg | Placebo |
|---|---|---|---|
| Day 4 | 25.2 | 25.4 | 23.8 |
| Day 7 | 51.6 | 48.6 | 42.9 |
| Day 15 | 74.8 | 76.9 | 71.4 |
| Day 21 | 80.5 | 81.5 | 85.7 |
| Day 29 | 84.9 | 84.4 | 88.1 |
Clinical status of participants was assessed using 7-point ordinal scale ranges from: 1= death; 2= hospitalized, on invasive mechanical ventilation/ECMO; 3= hospitalized, on non-invasive ventilation/high flow oxygen devices; 4= hospitalized, requiring supplemental oxygen; 5= hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related/otherwise); 6= hospitalized, not requiring supplemental oxygen - no longer required ongoing medical care; 7= not hospitalized, higher score=less severity.
| scores on a scale | Sarilumab 200 mg | Sarilumab 400 mg | Placebo |
|---|---|---|---|
| Day 4 | 0.1 ± 0.9 | 0.1 ± 1.0 | 0.2 ± 0.9 |
| Day 7 | 0.7 ± 1.5 | 0.7 ± 1.6 | 0.7 ± 1.4 |
| Day 15 | 1.9 ± 1.8 | 2.0 ± 1.9 | 1.7 ± 1.8 |
| Day 21 | 2.3 ± 1.9 | 2.3 ± 1.9 | 2.5 ± 1.7 |
| Day 29 | 2.5 ± 1.9 | 2.5 ± 1.9 | 2.7 ± 1.6 |
Resolution of fever was defined as body temperature less than or equal to (\<=) 36.6 degree Celsius (°C) (axilla), or \<=37.2°C (oral), or \<=37.8°C (rectal or tympanic) for at least 48 hours without antipyretics/until discharge, whichever was sooner. Time to resolution of fever (in days) was calculated as: date of first occurrence/episode of the event (resolution of fever) - date of first dose + 1. Kaplan-Meier method was used for estimation.
| days | Sarilumab 200 mg | Sarilumab 400 mg | Placebo |
|---|---|---|---|
| Time to Resolution of Fever | 8.0 (7.00 to 9.00) | 9.0 (7.00 to 10.00) | 7.0 (6.00 to 12.00) |
Time to resolution of fever was defined as body temperature \<=36.6°C (axilla), or \<=37.2 °C (oral), or \<=37.8°C (rectal or tympanic) for at least 48 hours without antipyretics or until discharge, whichever was sooner. Improvement in oxygenation was defined as oxygen saturation (SpO2)/FiO2 of 50 or greater compared to the nadir SpO2/FiO2 for at least 48 hours, or until discharge, whichever was sooner. Nadir SpO2/FiO2 was the nadir (lowest value) at any point in the study. Time to resolution of fever and improvement in oxygenation (in days) was calculated as: date of first occurrence/episode of the event (resolution of fever and improvement in oxygenation) - date of first dose + 1. Kaplan-Meier method was used for estimation.
| days | Sarilumab 200 mg | Sarilumab 400 mg | Placebo |
|---|---|---|---|
| Time to Resolution of Fever and Improvement in Oxygenation | 9.0 (8.00 to 10.00) | 10.0 (9.00 to 13.00) | 8.0 (7.00 to 12.00) |
Fever was defined as body temperature greater than (\>) 37.4°C (axilla), or \>38.0 °C (oral), or \>38.4°C (rectal or tympanic) based on maximum value observed during a 24-hour period. Number of days with fever were reported. Least square (LS) mean and standard error (SE) were estimated using the analysis of covariance (ANCOVA) model with treatment group and randomization strata as fixed effects.
| days | Sarilumab 200 mg | Sarilumab 400 mg | Placebo |
|---|---|---|---|
| Number of Days With Fever | 1.2 ± 0.23 | 1.3 ± 0.21 | 1.8 ± 0.30 |
NEWS2: used to standardize assessment of acute-illness severity, track clinical condition of participants and to alert clinical teams to participant deterioration. NEWS2 score was based on 7 clinical parameters: respiration rate, oxygen saturation, supplemental oxygen, systolic blood pressure, pulse rate, level of consciousness, and temperature. A score of 0, 1, 2, and 3 was allocated to each parameter except supplemental oxygen (a score of 0 or 1 was allocated) and level of consciousness (a score of 0 or 3 was allocated), where 0 = normal health condition to 3 = worst health condition; higher score indicated more severity. All scores were summed to get an aggregate score. Aggregate NEWS2 score ranged from 0 to 19, with higher scores meaning more severity/higher risk. Percentage of participants in following clinical risk categories were reported: low risk (score 0 to 4); low to medium risk (score of 3 in any individual parameter); medium risk (score 5 to 6); high risk (score 7 to 19).
| percentage of participants | Sarilumab 200 mg | Sarilumab 400 mg | Placebo |
|---|---|---|---|
| Baseline: Low | 28.8 | 22.1 | 34.2 |
| Baseline: Low to Medium | 0 | 0 | 0 |
| Baseline: Medium | 34.2 | 37.4 | 27.8 |
| Baseline: High | 37.0 | 40.5 | 38.0 |
| Day 4: Low | 52.8 | 56.2 | 40.5 |
| Day 4: Low to Medium | 0.6 | 1.2 | 0 |
| Day 4: Medium | 19.5 | 16.6 | 28.6 |
| Day 4: High | 27.0 | 26.0 | 31.0 |
| Day 7: Low | 57.0 | 60.8 | 51.4 |
| Day 7: Low to Medium | 0 | 2.1 | 0 |
| Day 7: Medium | 20.0 | 10.5 | 20.3 |
| Day 7: High | 23.0 | 26.6 | 28.4 |
| Day 15: Low | 52.5 | 52.2 | 61.1 |
| Day 15: Low to Medium | 0 | 1.5 | 2.8 |
| Day 15: Medium | 21.3 | 19.4 | 13.9 |
| Day 15: High | 26.2 | 26.9 | 22.2 |
| Day 21: Low | 44.8 | 50.0 | 66.7 |
| Day 21: Low to Medium | 13.8 | 0 | 0 |
| Day 21: Medium | 24.1 | 21.1 | 8.3 |
| Day 21: High | 17.2 | 28.9 | 25.0 |
| Day 29: Low | 57.1 | 27.8 | 60.0 |
| Day 29: Low to Medium | 0 | 0 | 0 |
| Day 29: Medium | 14.3 | 27.8 | 20.0 |
| Day 29: High | 28.6 | 44.4 | 20.0 |
Time to NEWS2 \<2 and maintained for 24 hours: time (in days) from 1st dose of study drug until 1st occurrence of NEWS score of \<2 (maintained for 24 hours); calculated as: date of 1st occurrence/episode of event (NEWS score of \<2) - date of 1st dose + 1. NEWS2 score was based on 7 clinical parameters: respiration rate, oxygen saturation, supplemental oxygen, systolic blood pressure, pulse rate, level of consciousness, and temperature. A score of 0, 1, 2, and 3 was allocated to each parameter except supplemental oxygen (score of 0 or 1 was allocated) and level of consciousness (score of 0 or 3 was allocated), where 0=normal health condition to 3=worst health condition; higher score=more severity. All scores were summed to get an aggregate score which ranged from 0 to 19, with higher scores=more severity/higher risk. Kaplan-Meier method was used for analysis.
| days | Sarilumab 200 mg | Sarilumab 400 mg | Placebo |
|---|---|---|---|
| Time to National Early Warning Score of Less Than (<) 2 and Maintained for 24 Hours | 9.0 (7.00 to 10.00) | 9.0 (8.00 to 11.00) | 11.0 (8.00 to 14.00) |
The NEWS2 was used to standardize the assessment of acute-illness severity, track the clinical condition of participants, and to alert clinical teams to participant deterioration. NEWS2 score is based on 7 clinical parameters: respiration rate, oxygen saturation, supplemental oxygen, systolic blood pressure, pulse rate, level of consciousness, and temperature. A score of 0, 1, 2, and 3 was allocated to each parameter except supplemental oxygen (a score of 0 or 1 was allocated) and level of consciousness (a score of 0 or 3 was allocated), where 0 = normal health condition to 3 = worst health condition; higher score indicated more severity. All scores were summed to get an aggregate score. Aggregate NEWS2 score ranged from 0 to 19, with higher scores meaning more severity/higher risk. LS means and SE were estimated using ANCOVA model with treatment group and randomization strata as fixed effects, and baseline NEWS2 score as a covariate.
| scores on a scale | Sarilumab 200 mg | Sarilumab 400 mg | Placebo |
|---|---|---|---|
| Day 4 | -1.07 ± 0.212 | -1.25 ± 0.198 | -0.36 ± 0.274 |
| Day 7 | -1.63 ± 0.265 | -1.47 ± 0.245 | -0.83 ± 0.338 |
| Day 15 | -2.10 ± 0.508 | -1.83 ± 0.467 | -2.36 ± 0.641 |
| Day 21 | -3.02 ± 0.769 | -2.24 ± 0.676 | -2.96 ± 1.090 |
| Day 29 | -2.57 ± 0.936 | -1.27 ± 0.884 | -3.64 ± 1.508 |
Time-to-improvement in oxygenation was defined as increase in SpO2/FiO2 of 50 or greater compared to the nadir SpO2/FiO2 for at least 48 hours or until discharge, whichever was sooner. Nadir SpO2/FiO2 was the nadir (lowest value) at any point in the study. Time to improvement in oxygenation was calculated as: date of first occurrence/episode of the event (oxygenation) - date of first dose + 1. Kaplan-Meier method was used for estimation.
| days | Sarilumab 200 mg | Sarilumab 400 mg | Placebo |
|---|---|---|---|
| Time-to-improvement in Oxygenation | 6.0 (5.00 to 7.00) | 6.0 (5.00 to 7.00) | 7.0 (5.00 to 8.00) |
Supplemental oxygen was defined as oxygen administration by nasal cannula, simple face mask, or other similar oxygen delivery device.
| percentage of participants | Sarilumab 200 mg | Sarilumab 400 mg | Placebo |
|---|---|---|---|
| Percentage of Participants Alive Off Supplemental Oxygen at Day 29 | 84.9 | 83.8 | 86.9 |
Hypoxemia (low level of oxygen in the blood) was defined as SpO2 \<93% on room air, or required supplemental oxygen, or mechanical ventilatory support. Days meeting the criteria for hypoxemia since the first study dose were counted and the percentage of days with hypoxemia were calculated as:100\*number of days with the hypoxemia divided by number of days of follow up (defined as the earlier date of death or discharge or last visit up to Day 29). LS mean and SE were estimated using the ANCOVA model with treatment group and randomization strata as fixed effects.
| percentage of days | Sarilumab 200 mg | Sarilumab 400 mg | Placebo |
|---|---|---|---|
| Percentage of Days With Hypoxemia | 73.01 ± 2.063 | 75.10 ± 1.941 | 76.32 ± 2.724 |
Supplemental oxygen (oxygen therapy) was defined as oxygen administration using oxygen delivery device (e.g. nasal cannula, simple face mask, non-rebreather mask, high flow nasal cannula, non-invasive ventilation, invasive mechanical ventilation, extracorporeal life support, etc.). Days meeting the criteria for supplemental oxygen use since the first study dose were counted and the percentage of days with supplemental oxygen use were calculated as:100\*number of days with the supplemental oxygen use divided by number of days of follow up (defined as the earlier date of death or discharge or last visit up to Day 29) . LS mean and SE were estimated using the ANCOVA model with treatment group and randomization strata as fixed effects.
| percentage of days | Sarilumab 200 mg | Sarilumab 400 mg | Placebo |
|---|---|---|---|
| Percentage of Days With Supplemental Oxygen Use | 70.57 ± 2.082 | 73.30 ± 1.959 | 73.23 ± 2.748 |
Resting respiratory rate was measured in terms of number of breaths per minute (bpm) while a person is at rest. Only the days with respiratory rate \>24 breath per minute since the first dose were counted and percentage of days with respiratory rate \> 24 bpm were calculated as:100\*number of days with respiratory rate \>24 bpm divided by number of days of follow up (defined as the earlier date of death or discharge or last visit up to Day 29). LS mean and SE were estimated using the ANCOVA model with treatment group and randomization strata as fixed effects.
| percentage of days | Sarilumab 200 mg | Sarilumab 400 mg | Placebo |
|---|---|---|---|
| Percentage of Days With Resting Respiratory Rate > 24 Breaths Per Minute | 14.74 ± 1.582 | 14.58 ± 1.485 | 15.74 ± 2.105 |
Time to oxygen saturation \>=94% on room air was defined as the time (in days) from first dose of study drug until the time of first occurrence of oxygen saturation \>=94% and it was calculated as: Date of first occurrence/episode of the event (oxygen saturation \>=94%) - date of first dose + 1.Kaplan-Meier method was used for estimation.
| days | Sarilumab 200 mg | Sarilumab 400 mg | Placebo |
|---|---|---|---|
| Time to Oxygen Saturation >= 94% on Room Air | 8.0 (6.00 to 10.00) | 8.0 (8.00 to 11.00) | 8.0 (7.00 to 11.00) |
Mean number of ventilator free days in participants were reported.
| days | Sarilumab 200 mg | Sarilumab 400 mg | Placebo |
|---|---|---|---|
| Mean Number of Ventilator Free Days | 23.8 ± 9.4 | 24.0 ± 8.8 | 24.9 ± 8.6 |
Percentage of participants With initiation of mechanical ventilation or non-invasive ventilation, or use of high flow nasal cannula were reported in this outcome measure.
| percentage of participants | Sarilumab 200 mg | Sarilumab 400 mg | Placebo |
|---|---|---|---|
| Percentage of Participants With Initiation of Mechanical Ventilation, Non-invasive Ventilation, or Use of High Flow Nasal Cannula | 20.5 | 23.4 | 19.1 |
Rescue medications were defined as the immunosuppressive (methylprednisolone, dexamethasone and prednisone) therapies. During the course of the study, participant who required rescue therapy was based on the judgement of the study physician.
| percentage of participants | Sarilumab 200 mg | Sarilumab 400 mg | Placebo |
|---|---|---|---|
| Percentage of Participants Who Required Rescue Medication | 13.8 | 15.0 | 22.6 |
Percentage of participants who needed ICU care until Day 29 were reported for those not in an ICU at baseline.
| percentage of participants | Sarilumab 200 mg | Sarilumab 400 mg | Placebo |
|---|---|---|---|
| Percentage of Participants Who Needed Intensive Care Unit (ICU) Care During Study | 11.2 | 14.9 | 12.5 |
Number of days of hospitalization among alive participants were counted at Day 60 since the first dose. LS mean and SE were estimated using the ANCOVA model with treatment group and randomization strata as fixed effects.
| days | Sarilumab 200 mg | Sarilumab 400 mg | Placebo |
|---|---|---|---|
| Number of Days of Hospitalization Among Survivors (Alive Participants) | 15.6 ± 0.96 | 16.1 ± 0.91 | 15.9 ± 1.27 |
An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had to have a causal relationship with the treatment. Treatment-emergent AEs (TEAEs) were the AEs that developed or worsened or became serious during the TEAE period (from the time of first dose of study drug to the last dose of study drug + 60 days). SAEs were any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event.
| Participants | Sarilumab 200 mg | Sarilumab 400 mg | Placebo |
|---|---|---|---|
| Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) | 42 | 51 | 20 |
Major or opportunistic bacterial or fungal infections was considered as an adverse event of special interest (AESI: defined as an AE \[serious or non-serious\] of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor was required).
| Participants | Sarilumab 200 mg | Sarilumab 400 mg | Placebo |
|---|---|---|---|
| Number of Participants With Major or Opportunistic Bacterial or Fungal Infections | 8 | 15 | 3 |
Grade 4 neutropenia was defined as participants with absolute neutrophil count (ANC) \<500 per cubic millimeter (mm\^3). Grade 4 neutropenia with concurrent invasive infection was defined as infections and infestations (in participants with Grade 4 neutropenia) within 1 week of ANC \<500/mm\^3 and was considered as an AESI (defined as an AE \[serious or non-serious\] of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor was required).
| Participants | Sarilumab 200 mg | Sarilumab 400 mg | Placebo |
|---|---|---|---|
| Grade 4 neutropenia | 3 | 6 | 0 |
| Grade 4 neutropenia with concurrent invasive infection | 0 | 0 | — |
Grade \>=2 (moderate) infusion related reactions (defined as any TEAE signs or symptoms experienced by participants who received study medication within 24 hours of the start of infusion) and Grade \>=2 (moderate) hypersensitivity reactions (anaphylactic reaction, hypersensitivity or angioedema and moderate reactions) were considered as AESI which was defined as an AE (serious or non-serious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor was required. Gastrointestinal Perforation was defined as formation of a hole through the stomach, large bowel or small intestine.
| Participants | Sarilumab 200 mg | Sarilumab 400 mg | Placebo |
|---|---|---|---|
| Grade >=2 Infusion related reactions | 1 | 6 | 0 |
| Grade >=2 Hypersensitivity reactions | 1 | 7 | 0 |
| Gastrointestinal perforation | 1 | 0 | 0 |
Criteria for PCSA: * Hemoglobin: less than or equal to (\<=) 115 grams per liter (g/L) (male) and \<=95 g/L (female); greater than or equal to (\>=) 185 g/L (male) and \>=165 g/L (female); and decrease from baseline \>=20 g/L. * Leukocytes: \<3.0\*10\^9/Liters (L) (Non-Black) or \<2.0\*10\^9/L (black); \>=16.0\*10\^9/L. * Platelets: \< 100\*10\^9/L; \>=700\*10\^9/L.
| Participants | Sarilumab 200 mg | Sarilumab 400 mg | Placebo |
|---|---|---|---|
| Hemoglobin <=115 g/L (male) and <=95 g/L (female) | 29 | 34 | 15 |
| Hemoglobin >=185 g/L (male) and >=165 g/L (female) | 0 | 0 | 0 |
| Hemoglobin decrease from baseline >=20 g/L | 32 | 30 | 15 |
| Leukocytes <3.0*10^9/L (Non-Black) or <2.0*10^9/L (black) | 19 | 31 | 1 |
| Leukocytes >=16*10^9/L | 13 | 21 | 6 |
| Platelets <100*10^9/L | 2 | 7 | 3 |
| Platelets >=700*10^9/L | 3 | 2 | 2 |
Criteria for PCSA: Creatinine: \>=150 micromoles per liter (mcmol/L); \>=30% change from baseline; \>= 100% change from baseline.
| Participants | Sarilumab 200 mg | Sarilumab 400 mg | Placebo |
|---|---|---|---|
| Creatinine >=150 mcmol/L | 15 | 15 | 5 |
| >=30% change from baseline in Creatinine | 31 | 30 | 10 |
| >=100% change from baseline in Creatinine | 6 | 7 | 3 |
* Alanine Aminotransferase (ALT): \>3 upper limit of normal (ULN); \>5 ULN; \>10 ULN and \>20 ULN. * Bilirubin: \>1.5 ULN; \>2 ULN.
| Participants | Sarilumab 200 mg | Sarilumab 400 mg | Placebo |
|---|---|---|---|
| ALT >3 ULN | 60 | 63 | 24 |
| ALT >5 ULN | 28 | 25 | 12 |
| ALT >10 ULN | 6 | 5 | 3 |
| ALT >20 ULN | 1 | 0 | 0 |
| Bilirubin >1.5 ULN | 5 | 4 | 4 |
| Bilirubin >2 ULN | 4 | 2 | 2 |
Collected over All AEs were collected from the time of first dose of study drug up to 60 days regardless of seriousness or relationship to study drug.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sarilumab 200 mg | 17/159 (10.7%) | 42/159 (26.4%) | 57/159 (35.8%) |
| Sarilumab 400 mg | 18/173 (10.4%) | 51/173 (29.5%) | 68/173 (39.3%) |
| Placebo | 9/84 (10.7%) | 20/84 (23.8%) | 14/84 (16.7%) |
| Event | Sarilumab 200 mg | Sarilumab 400 mg | Placebo |
|---|---|---|---|
| Covid-19 PneumoniaInfections and infestations | 11/159 | 4/173 | 2/84 |
| Respiratory FailureRespiratory, thoracic and mediastinal disorders | 6/159 | 5/173 | 3/84 |
| Atrial FibrillationCardiac disorders | 0/159 | 0/173 | 3/84 |
| Multiple Organ Dysfunction SyndromeGeneral disorders | 2/159 | 3/173 | 3/84 |
| PneumoniaInfections and infestations | 1/159 | 6/173 | 0/84 |
| Septic ShockInfections and infestations | 4/159 | 4/173 | 2/84 |
| Alanine Aminotransferase IncreasedInvestigations | 4/159 | 3/173 | 1/84 |
| Bacterial InfectionInfections and infestations | 0/159 | 1/173 | 2/84 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 1/159 | 2/173 | 2/84 |
| Acute Kidney InjuryRenal and urinary disorders | 2/159 | 4/173 | 0/84 |
| Event | Sarilumab 200 mg | Sarilumab 400 mg | Placebo |
|---|---|---|---|
| Alanine Aminotransferase IncreasedInvestigations | 48/159 | 58/173 | 14/84 |
| Aspartate Aminotransferase IncreasedInvestigations | 11/159 | 15/173 | 0/84 |
| NeutropeniaBlood and lymphatic system disorders | 11/159 | 13/173 | 0/84 |
Analysis was performed on randomized population.
| Age, Continuous(years) | Sarilumab 200 mg | Sarilumab 400 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 58.3 ± 13.7 | 58.0 ± 14.1 | 59.9 ± 14.8 | 58.5 ± 14.1 |
| Sex: Female, Male(Participants) | Sarilumab 200 mg | Sarilumab 400 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 52 | 74 | 30 | 156 |
| Male | 109 | 99 | 56 | 264 |
| Race (NIH/OMB)(Participants) | Sarilumab 200 mg | Sarilumab 400 mg | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 2 | 1 | 5 |
| Asian | 5 | 9 | 6 | 20 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 1 |
| Black or African American | 3 | 5 | 1 | 9 |
| White | 128 | 128 | 69 | 325 |
| More than one race | 0 | 3 | 0 | 3 |
| Unknown or Not Reported | 23 | 26 | 8 | 57 |
| Clinical Status: 7-point ordinal scale(Participants) | Sarilumab 200 mg | Sarilumab 400 mg | Placebo | Total |
|---|---|---|---|---|
| Scale Score 1 | 0 | 0 | 0 | 0 |
| Scale Score 2 | 17 | 24 | 10 | 51 |
| Scale Score 3 | 28 | 21 | 11 | 60 |
| Scale Score 4 | 113 | 128 | 65 | 306 |
| Scale Score 5 | 3 | 0 | 0 | 3 |
| Scale Score 6 | 0 | 0 | 0 | 0 |
| Scale Score 7 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Mar 2020 to primary completion in Jul 2020, 4 months.
Results were first posted in May 2021, 9 months after primary completion.
Of 35 industry-sponsored phase 3 interventional studies under Coronavirus Infections, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 25. This study's 4 months is below that.
Counting every sponsor, half of 91 studies reached it within 11 months; a quarter within 5 and three quarters within 20.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sarilumab